Evidence map›Paper›PMID 39677831›Full record

ArticleInternational journal of chronic obstructive pulmonary disease2024

COVID-19 in Individuals with Severe Alpha 1-Antitrypsin Deficiency.

Hanan Tanash, Erona Tahiri Blakaj, Eeva Piitulainen, Suneela Zaigham

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of chronic obstructive pulmonary disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hanan TanashDepartment of Medicine, Skåne University Hospital, Lund University, Lund, Sweden.
Erona Tahiri BlakajDepartment of Medicine, Skåne University Hospital, Lund University, Lund, Sweden.
Eeva PiitulainenDepartment of Medicine, Skåne University Hospital, Lund University, Lund, Sweden.
Suneela ZaighamDepartment of Clinical Sciences, Lund University, Lund, Sweden.ORCID 0000-0002-9132-5665

Funding

Swedish Heart- Lung Foundation
6 · The paper itself

Abstract

Background: The risk of coronavirus (COVID-19) can be affected by the presence of certain chronic conditions. It is unknown if individuals with severe hereditary alpha-1-antitrypsin deficiency (AATD) faced an increased risk of severe COVID-19 infection during the pandemic and if COPD in this population affected the risk of severe COVID-19 outcomes. Aim: Our aim was to investigate COVID-19 outcomes in individuals with severe AATD and to identify if COPD was a risk factor for severe disease. Methods: Between 2021-2023 we interviewed 863 individuals with severe AATD (phenotype PiZZ) included in the Swedish National AATD Registry. Details on COVID-19 outcomes were collected. Cox regression models were used to assess risk of mild and severe COVID-19 by presence of COPD. Results: Of 863 subjects with severe AATD, 231 reported COVID-19 infection (208 mild and 23 severe COVID-19). Subjects with severe COVID-19 were older, had lower FEV Conclusion: Most patients with severe AATD exhibit mild symptoms of COVID-19 infection, managing them in the community. Patients who also have COPD are at increased risk of severe COVID-19 infection.

Indexed as

alpha 1-Antitrypsin DeficiencyCOVID-19Pulmonary Disease, Chronic ObstructiveRegistriesSeverity of Illness IndexAdultAgedComorbidityFemaleHumansMaleMiddle AgedRisk AssessmentRisk FactorsSARS-CoV-2Swedenalpha-1-antitrypsin deficiencyCOPDCOVID-19

Identifiers

PMID39677831
PMCPMC11639877

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.